Jonathan Clavell Hernandez, MD
Urology · Houston, TXNPI 1619230869
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Coloplast accounts for 62.8% of it on its own, with 23 other manufacturers making up the rest. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 997 payments — averaging $501.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$314K
- Boston Scientific$166K
- Endo Pharmaceuticals Inc.$17K
- Astellas Pharma US Inc$821
- Pfizer$559
- Endo USA, Inc.$432
- plus $1K from 18 others
What the payments were for
- Consulting fees$278,36856%
- Speaking & faculty fees$136,16927%
- Travel & lodging$12,7553%
- Food & beverage$40,3928%
- Education$32,5607%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 470 | $314,172 |
| Boston Scientific | 336 | $166,159 |
| Endo Pharmaceuticals Inc. | 56 | $16,675 |
| Astellas Pharma US Inc | 37 | $821 |
| Pfizer | 24 | $559 |
| Endo USA, Inc. | 15 | $432 |
| Antares Pharma, Inc. | 17 | $341 |
| Verity Pharmaceuticals Inc. | 9 | $183 |
| Axonics, Inc. | 5 | $175 |
| Valencia Technologies Corporation | 1 | $127 |
| Convatec Inc. | 4 | $90 |
| Acerus Pharmaceuticals Corporation | 4 | $71 |
| Tolmar, Inc. | 2 | $69 |
| Angiodynamics, Inc. | 2 | $65 |
| Ferring Pharmaceuticals Inc. | 3 | $57 |
| Teleflex LLC | 2 | $39 |
| 180 Medical, Inc. | 2 | $39 |
| Neotract Inc. | 1 | $33 |
| Innovation Technologies Inc | 1 | $33 |
| Mission Pharmacal Company | 2 | $29 |
| Olympus America Inc. | 1 | $24 |
| AbbVie | 1 | $18 |
| Halozyme Inc | 1 | $16 |
| Duchesnay USA Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$296,572
- AMS 700 CXR RTE KIT$68,806
- GENERAL ERECTILE DYSFUNCTION$18,685
- XIAFLEX$15,973
- TACTRA$12,400
- rezum Generator$10,677
- AMS$8,876
- REZUM$7,360
- UPSYLON$3,850
- ADVANCE$2,650
- AdVance XP$2,069
- AMS 700$1,557
- GENERAL - THERAPIES$1,340
- SenSura Mio$580
- SPECTRA WAVEWRITER$359
- GENERAL BPH$243
- GREENLIGHT$170
- eCoin Device Kit$127
- VORTEK$113
- PENILE & TESTICULAR RECONSTRUCTN$101
How this compares
$500,244 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 22 | $22,117 |
| XyostedTestosterone Enanthate | 18 | $14,212 |
| Cabergoline | 29 | $1,915 |
| Testosterone | 17 | $1,594 |
| Tamsulosin Hcl | 154 | $1,582 |
| Tadalafil | 17 | $1,441 |
| Testosterone Cypionate | 38 | $1,392 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,179 |
| Cephalexin | 68 | $475 |
| Ketorolac Tromethamine | 27 | $453 |
| Gabapentin | 69 | $401 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 93 | $285 |
| Finasteride | 19 | $87 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $82 |
| Tramadol Hcl | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $821 | $22,11722 claims |
| Antares Pharma, Inc.Xyosted | $341 | $14,21218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
- Steven MaislosHouston$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.